Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer

NCT02623621 · clinicaltrials.gov ↗

COMPLETED

Status

103

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: chemotherapy plus bevacizumab

Sponsor

Azienda Ospedaliero, Universitaria Pisana